Triple-negative breast cancer (TNBC) is a subtype of breast tumor with unique
characteristics in terms of clinical− pathological presentation, prognosis, and response to …

Chemotherapy treatments are considered essential tools to defeat cancer progression and
dissemination to improve patients' quality of life and survival. Although most malignancies …

Deciphering the cellular and molecular interactions that drive disease within the tissue
microenvironment holds promise for discovering drug targets of the future. In order to …

Despite decades of research, efforts to directly target KRAS have been challenging.
MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS-and autophagy-
dependent tumorigenic growth, but the role of KRAS in supporting autophagy has not been …

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant
Colorectal Cancer - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Little is known about the preanalytical fluctuations of phosphoproteins during tissue
procurement for molecular profiling. This information is crucial to establish guidelines for the …

Induction of compensatory mechanisms and ERK reactivation has limited the effectiveness
of Raf and MEK inhibitors in RAS-mutant cancers. We determined that direct pharmacologic …

Allele-specific signaling by different KRAS alleles remains poorly understood. The KRAS
G12R mutation displays uneven prevalence among cancers that harbor the highest …

Mutational loss of CDKN2A (encoding p16INK4A) tumor-suppressor function is a key
genetic step that complements activation of KRAS in promoting the development and …